Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
43.10
-0.70 (-1.60%)
At close: Jul 19, 2024, 4:00 PM
43.14
+0.04 (0.09%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 42.09, with a low estimate of 24 and a high estimate of 56. The average target predicts a decrease of -2.34% from the current stock price of 43.10.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for KYMR stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 4 | 3 | 3 | 3 |
| Hold | 5 | 5 | 5 | 5 | 5 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $52 | Buy | Maintains | $52 | +20.65% | Jul 10, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $31 → $36 | Hold | Maintains | $31 → $36 | -16.47% | Jul 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +6.73% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +6.73% | Jun 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | -30.39% | May 24, 2024 |
Financial Forecast
Revenue This Year
53.21M
from 78.59M
Decreased by -32.30%
Revenue Next Year
68.79M
from 53.21M
Increased by 29.28%
EPS This Year
-2.90
from -2.52
EPS Next Year
-3.15
from -2.90
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 110.6M | 135.6M | 284.6M | 834.8M | 1.1B |
| Avg | 53.2M | 68.8M | 75.9M | 118.2M | 219.9M |
| Low | 14.9M | 14.1M | n/a | -39.2M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 40.7% | 154.8% | 313.7% | 999.7% | 863.0% |
| Avg | -32.3% | 29.3% | 10.3% | 55.7% | 86.1% |
| Low | -81.0% | -73.5% | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.02 | -1.40 | -1.62 | 4.18 | 6.15 |
| Avg | -2.90 | -3.15 | -3.19 | -2.93 | -2.00 |
| Low | -3.64 | -4.16 | -4.97 | -5.03 | -4.51 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.